Tarsa Therapeutics Inc - Company Review
Tarsa Therapeutics Inc - Company ReviewSummary
Tarsa Therapeutics Inc (Tarsa) develops therapies for the treatment and prevention of osteoporosis and other bone related diseases. The company develops TBRIA, an oral formulation of calcitonin, a peptide hormone that inhibits bone resorption, which is used for the treatment of postmenopausal osteoporosis in women at least five years post menopause. The company also offers osteoporosis treatment and osteoporosis prevention clinical programs. Tarsa is headquartered in Philadelphia, Pennsylvania, the US.
This comprehensive company report of Tarsa Therapeutics Inc provides you with company's businesses and operations information.
The profile contains critical company information including,
- Company Overview - A detailed description of the company's operations and business divisions.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.
Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.